This presentation will review recent advances in the treatment of high-risk neuroblastoma, including the use of tandem high-dose chemotherapy, therapeutic 131|-mIBG and the incorporation of targeted molecular therapy into upfront treatment protocols. The role of anti-GD2 based immunotherapy in the treatment of neuroblastoma in both the upfront and relapse settings and other potential strategies for treating relapsed or refractory high-risk disease will also be discussed. Finally, future potential therapies for neuroblastoma will be outlined.
Daniel Morgenstern, MB BChir, PhD,
Director of New Agent and Innovative Therapies Program and Therapeutic MIBG Program,
The Hospital for Sick Children
Dr. Daniel Morgenstern is Staff Oncologist at The Hospital for Sick Children and Assistant Professor at the University of Toronto. He originally qualified from University of Cambridge, UK, and followed this with postgraduate education at Great Ormond Street Hospital in London. He was an academic clinical lecturer at UCL Institute of Child Health, trained in drug development at the Royal Marsden Hospital and was the first Sears Foundation/Garron Cancer Centre Fellow in Neuroblastoma at SickKids. He subsequently worked as a consultant in pediatric oncology at Great Ormond Street Hospital where he was clinical lead for the neuroblastoma and autograft programs. He moved back to SickKids in 2016 as Director of the New Agent and Innovative Therapy (NAIT) and Therapeutic mIBG Programs and as co-lead of the neuroblastoma service. His clinical activities are focused on neuroblastoma and solid tumour patients participating in early phase clinical trials. His research interests are in early phase trials and, in particular, the use of immune checkpoint inhibitors in pediatric cancers and the development of precision medicine approaches for pediatric solid tumours.